/

AGIO

Agios Pharmaceuticals, Inc.Pre-market

30.82−0.99 −3.11%USD

NasdaqGS · as of Oct 12, 16:00 ET · 15m delay

Open

31.88

Prev close

31.81

Day range

30.6932.22

52-week range

22.2446.00

Volume

647.84K0.61×

Mkt cap

1.84B

P/E ttm

—

Fwd P/E

-7.66

EPS ttm

-7.01

Div yield

0.00%

Earnings

Nov 5, 2026

From 52w high

−33.00%

Price Chart

Yahoo Finance · delayed

AGIOOct 12, 2026O 31.84H 32.22L 30.69C 30.82−0.99 (−3.11%)Vol 647.80K

SMA 5033.08
SMA 20031.21

1Y change −24.11% since Oct 10, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

AGIO Agios Pharmaceuticals, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −1.38%
1 month: −8.27%
3 months: −24.00%
6 months: −7.03%
Year to date: +13.23%
1 year: −24.11%

Valuation & ownership

Market cap: 1.84B
Enterprise value: 1.25B
P/E (ttm): —
Forward P/E: -7.66
PEG ratio: —
Price / book: 1.79
Price / sales (ttm): 18.71
EV / EBITDA: -2.76
EPS (ttm): -7.01
EPS (forward): -4.02
Beta (5y monthly): 0.63
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 59.70M
Float: 50.02M
Short % of float: 11.87%
Short ratio (days): 7.21
Held by insiders: 1.07%
Held by institutions: 112.29%
Avg volume (3m): 1.07M
50-day average: 33.08
200-day average: 31.21
52-week change: −24.11%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 36.2
vs 50-day SMA: −6.84%
vs 200-day SMA: −1.24%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 4.08%
Realised vol (20d, ann.): 31.4%
From 52-week high: −33.00%
From 52-week low: +38.58%

ANR

Analyst Consensus

8 analysts

Consensus

Buy

1.60 on a 1 (strong buy) – 5 (sell) scale

Mean target

46.00

+49.25% implied

Low 32.00Median 43.50High 73.00

Recommendation trend

Now7 / 3 / 0
1m ago7 / 3 / 0

DES

About Agios Pharmaceuticals, Inc.

Yahoo Finance profile

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Sector: Healthcare
Industry: Biotechnology
Employees: 539
Headquarters: Cambridge, MA, United States
Website: agios.com
Officers: Mr. Brian M. Goff M.B.A. CEO & Director
Ms. Cecilia Jones Chief Financial Officer
Dr. Krishnan Viswanadhan M.B.A., Pharm.D.

SEAS

Seasonality · AGIO

2013–2026 · monthly returns

Strongest month Feb +5.71%Weakest month Dec −5.14%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	0.8	10.2	11.9	-17.2	5.0	26.2	-19.1	12.2	-1.3	-7.3			+13.2%
2025	4.7	3.3	-17.6	1.3	8.1	3.6	11.9	1.3	6.4	7.7	-32.5	-6.8	−17.2%
2024	1.6	42.9	-9.5	11.1	11.8	18.7	7.6	-1.1	-3.2	0.0	33.7	-44.7	+47.6%
2023	5.0	-14.1	-9.2	-0.4	10.5	12.0	-6.4	3.4	-9.8	-15.1	5.8	0.2	−20.7%
2022	-6.0	0.8	-6.5	-24.5	-11.4	13.9	-2.7	18.2	10.9	-2.6	9.4	-6.8	−14.6%
2021	8.4	1.0	8.9	8.1	-0.0	-1.2	-12.7	-7.1	3.3	1.8	-24.2	-7.7	−24.1%
2020	2.1	-2.6	-25.3	16.0	25.8	3.4	-15.3	-9.5	-14.7	14.5	15.6	-6.5	−9.3%
2019	16.2	21.0	4.0	-17.1	-17.4	8.0	-3.5	-21.1	-14.6	-7.2	29.3	22.8	+3.6%
2018	37.8	2.1	1.7	2.6	11.4	-9.9	2.6	-6.6	-4.5	-18.2	4.3	-29.9	−19.3%
2017	3.1	12.6	20.6	-14.9	-6.1	10.2	8.7	13.1	5.5	-3.7	-4.2	-7.1	+37.0%
2016	-35.0	-9.2	5.9	20.6	14.3	-25.1	7.9	-18.5	43.4	-9.4	21.7	-28.3	−35.7%
2015	3.5	-7.5	-12.1	-2.1	32.1	-8.9	-0.9	-21.6	-18.3	3.2	-11.4	0.5	−42.1%
2014	10.4	18.2	25.2	7.4	-16.4	30.3	-12.0	14.7	32.7	37.0	20.0	11.1	+367.8%
2013								-19.1	18.6	-17.2	-24.2	36.5	−17.9%

INSD

Insider Activity · AGIO

Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

91.7K shares

Sells, 6 months

34K shares

Net shares

+57.7K

Net change in insider shares

+10.00%

Date	Insider	Transaction	Shares	Value
Aug 3, 2026	Gheuens SarahOfficer	Sale at price 30.48 per share.	30K	$914.40K
Jul 7, 2026	Backstrom Jay TDirector	Stock Award(Grant) at price 0.00 per share.	1.4K	—
Jul 7, 2026	Backstrom Jay TDirector	Conversion of Exercise of derivative security at price 42.76 per share.	1.4K	$61.87K
Jun 30, 2026	Gheuens SarahOfficer	Sale at price 37.56 per share.	4K	$150.50K
Jun 30, 2026	Gheuens SarahOfficer	—	8.4K	—
Jun 17, 2026	Capello Jeffrey DDirector	—	2.8K	—
Jun 17, 2026	Foster-Cheek Kaye IDirector	—	2.8K	—
Jun 17, 2026	Fouse Jacqualyn A.Director	—	2.8K	—
Jun 17, 2026	Smith CynthiaDirector	—	2.8K	—
Jun 17, 2026	Goff BrianChief Executive Officer	Conversion of Exercise of derivative security at price 34.16 per share.	39K	$1.33M
Jun 17, 2026	Scadden David T.Director	—	2.8K	—
Jun 17, 2026	Ballal Rahul D.Director	—	2.8K	—
Jun 17, 2026	Adams Catherine OwenDirector	—	2.8K	—
Jun 17, 2026	Jones CeciliaChief Financial Officer	Conversion of Exercise of derivative security at price 34.16 per share.	3K	$102.48K
Jun 17, 2026	Ho MaykinDirector	—	2.8K	—
Jun 17, 2026	Gheuens SarahOfficer	Conversion of Exercise of derivative security at price 34.16 per share.	3K	$102.48K
Jun 17, 2026	Burns James WilliamOfficer	Conversion of Exercise of derivative security at price 34.16 per share.	3K	$102.48K
Jun 17, 2026	Milanova TsvetaOfficer	Conversion of Exercise of derivative security at price 34.16 per share.	3K	$102.48K
Jun 17, 2026	Viswanadhan KrishnanOfficer	Conversion of Exercise of derivative security at price 34.16 per share.	3K	$102.48K
Jun 11, 2026	Capello Jeffrey DDirector	—	2K	—

CONG

Congress Trades · AGIO

House reports since 2025

Members

1 last bought

Buys

~$40.0K

Sells

~$0

Net

+$40.0K

est. bought − sold

Latest

Aug 20, 26

Gilbert Cisneros

Members who traded it

Member	Buys	Sells	Est. net	Last move
Gilbert Cisneros CA31	5		+$40.0K	Bought Aug 20, 26

Bought and sold by quarter (est.)

House members' AGIO trades, newest first
Traded	Member	Owner	Type	Amount	Filed	Report
Aug 20, 26	Gilbert Cisneros CA31	Self	Buy	$1,001 - $15,000	Sep 10, 26 (21d)	PDF
Mar 3, 26	Gilbert Cisneros CA31	Self	Buy	$1,001 - $15,000	Apr 7, 26 (35d)	PDF
Dec 11, 25	Gilbert Cisneros CA31	Self	Buy	$1,001 - $15,000	Jan 12, 26 (32d)	PDF
Apr 17, 25	Gilbert Cisneros CA31	Self	Buy	$1,001 - $15,000	May 6, 25 (19d)	PDF
Jan 29, 25	Gilbert Cisneros CA31	Self	Buy	$1,001 - $15,000	Feb 11, 25 (13d)	PDF

From the House's STOCK Act reports (Senate not included). Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades

AGIO

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

AGIO

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Agios Pharmaceuticals, Inc.

Seasonality · AGIO

Insider Activity · AGIO

Congress Trades · AGIO

Members who traded it

Bought and sold by quarter (est.)

Congress Trades · AGIO

Members who traded it

Bought and sold by quarter (est.)

Insider Activity · AGIO

Seasonality · AGIO

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Agios Pharmaceuticals, Inc.

Financial Snapshot

Earnings & Dividends

News